483 related articles for article (PubMed ID: 34063339)
1. Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
Iervolino M; Lepore E; Forte G; Laganà AS; Buzzaccarini G; Unfer V
Nutrients; 2021 May; 13(5):. PubMed ID: 34063339
[TBL] [Abstract][Full Text] [Related]
2. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
Advani K; Batra M; Tajpuriya S; Gupta R; Saraswat A; Nagar HD; Makwana L; Kshirsagar S; Kaul P; Ghosh AK; Pradhan S; Mehta A; Jaiswal A; Nakhate KT; Kamdi S
J Obstet Gynaecol; 2020 Jan; 40(1):96-101. PubMed ID: 31339394
[TBL] [Abstract][Full Text] [Related]
4. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
5. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
6. Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature.
Menichini D; Ughetti C; Monari F; Di Vinci PL; Neri I; Facchinetti F
Gynecol Endocrinol; 2022 Aug; 38(8):623-631. PubMed ID: 35713558
[No Abstract] [Full Text] [Related]
7. The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner's Results.
Fedeli V; Catizone A; Querqui A; Unfer V; Bizzarri M
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047265
[TBL] [Abstract][Full Text] [Related]
8. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.
Romero-Ruiz A; Skorupskaite K; Gaytan F; Torres E; Perdices-Lopez C; Mannaerts BM; Qi S; Leon S; Manfredi-Lozano M; Lopez-Rodriguez C; Avendaño MS; Sanchez-Garrido MA; Vazquez MJ; Pinilla L; van Duin M; Kohout TA; Anderson RA; Tena-Sempere M
Hum Reprod; 2019 Dec; 34(12):2495-2512. PubMed ID: 31820802
[TBL] [Abstract][Full Text] [Related]
9. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
[TBL] [Abstract][Full Text] [Related]
10. Decreased Insulin Resistance by Myo-Inositol Is Associated with Suppressed Interleukin 6/Phospho-STAT3 Signaling in a Rat Polycystic Ovary Syndrome Model.
Zhang Y; Li C; Zhang W; Zheng X; Chen X
J Med Food; 2020 Apr; 23(4):375-387. PubMed ID: 32045334
[TBL] [Abstract][Full Text] [Related]
11. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
12. Influence of Vitamin D on the Incidence of Metabolic Syndrome and Hormonal Balance in Patients with Polycystic Ovary Syndrome.
Lejman-Larysz K; Golara A; Baranowska M; Kozłowski M; Guzik P; Szydłowska I; Nawrocka-Rutkowska J; Sowińska-Przepiera E; Cymbaluk-Płoska A; Brodowska A
Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447279
[TBL] [Abstract][Full Text] [Related]
13. Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome.
Fruzzetti F; Capozzi A; Canu A; Lello S
Gynecol Endocrinol; 2019 Jun; 35(6):506-510. PubMed ID: 30612488
[TBL] [Abstract][Full Text] [Related]
14. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
[TBL] [Abstract][Full Text] [Related]
15. Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome.
Enli Y; Fenkci SM; Fenkci V; Oztekin O
Gynecol Endocrinol; 2013 Dec; 29(12):1036-9. PubMed ID: 23961784
[TBL] [Abstract][Full Text] [Related]
16. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
18. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
[TBL] [Abstract][Full Text] [Related]
19. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
Ates S; Aydın S; Ozcan P; Soyman Z; Gokmen Karasu AF; Sevket O
J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
[TBL] [Abstract][Full Text] [Related]
20. The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome.
Jamilian M; Samimi M; Mirhosseini N; Afshar Ebrahimi F; Aghadavod E; Talaee R; Jafarnejad S; Hashemi Dizaji S; Asemi Z
J Affect Disord; 2018 Oct; 238():32-38. PubMed ID: 29859385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
